Literature DB >> 17067186

Galantamine extended release in Alzheimer's disease: profile report.

Dean M Robinson1, Greg L Plosker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17067186     DOI： 10.2165/00002512-200623100-00006

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


× No keyword cloud information.
  10 in total

1.  Prevalence of AD among whites: a summary by levels of severity.

Authors:  L X Hy; D M Keller
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

Review 2.  Alzheimer's disease and Parkinson's disease.

Authors:  Robert L Nussbaum; Christopher E Ellis
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

Review 3.  Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies.

Authors:  Christopher M Clark; Jason H T Karlawish
Journal:  Ann Intern Med       Date:  2003-03-04       Impact factor: 25.391

4.  Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.

Authors:  Henry Brodaty; Jody Corey-Bloom; Felix C V Potocnik; Luc Truyen; Michael Gold; Chandrasekhar Rao V Damaraju
Journal:  Dement Geriatr Cogn Disord       Date:  2005-06-30       Impact factor: 2.959

5.  Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.

Authors:  Constantine G Lyketsos; Christopher C Colenda; Cornelia Beck; Karen Blank; Murali P Doraiswamy; Douglas A Kalunian; Kristine Yaffe
Journal:  Am J Geriatr Psychiatry       Date:  2006-07       Impact factor: 4.105

6.  Global prevalence of dementia: a Delphi consensus study.

Authors:  Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

Review 7.  Galantamine: a review of its use in Alzheimer's disease.

Authors:  L J Scott; K L Goa
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

8.  Galantamine extended release.

Authors:  Dean M Robinson; Greg L Plosker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

9.  Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers.

Authors:  Qinying Zhao; Luc Janssens; Tom Verhaeghe; H Robert Brashear; Luc Truyen
Journal:  Curr Med Res Opin       Date:  2005-10       Impact factor: 2.580

Review 10.  Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Authors:  Michael W Jann; Kara L Shirley; Gary W Small
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447
  10 in total
  1 in total

1.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.